GW Pharmaceuticals PLC- (NASDAQ:GWPH) Cut to Sell at BidaskClub

GW Pharmaceuticals PLC- (NASDAQ:GWPH) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, June 26th, BidAskClub reports.

A number of other research firms have also recently weighed in on GWPH. Guggenheim restated a “buy” rating and set a $222.00 price objective (up from $186.00) on shares of GW Pharmaceuticals PLC- in a research report on Tuesday, May 7th. CIBC increased their target price on shares of Stella-Jones from C$51.00 to C$53.00 in a research report on Tuesday, May 7th. Zacks Investment Research lowered shares of W. R. Grace & Co from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. ValuEngine raised shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, May 17th. Finally, Morgan Stanley reissued a “buy” rating on shares of GW Pharmaceuticals PLC- in a research report on Tuesday, April 9th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $205.40.

Shares of GWPH stock traded up $3.01 during trading hours on Wednesday, hitting $166.01. The company’s stock had a trading volume of 270,125 shares, compared to its average volume of 429,356. The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.19 and a current ratio of 7.81. The stock has a 50 day simple moving average of $173.18. GW Pharmaceuticals PLC- has a 12-month low of $90.14 and a 12-month high of $196.00. The stock has a market cap of $4.92 billion, a PE ratio of -15.66 and a beta of 2.32.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its earnings results on Monday, May 6th. The biopharmaceutical company reported ($1.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.48) by $0.80. The firm had revenue of $39.20 million during the quarter, compared to analysts’ expectations of $12.32 million. GW Pharmaceuticals PLC- had a negative net margin of 458.79% and a negative return on equity of 45.75%. The business’s revenue was up 1189.5% compared to the same quarter last year. During the same period in the previous year, the business posted ($3.12) EPS. Research analysts expect that GW Pharmaceuticals PLC- will post -4.76 EPS for the current year.

In other GW Pharmaceuticals PLC- news, CEO Justin D. Gover sold 202,224 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $15.24, for a total value of $3,081,893.76. Following the completion of the transaction, the chief executive officer now owns 743,765 shares in the company, valued at approximately $11,334,978.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Douglas B. Snyder sold 4,968 shares of the company’s stock in a transaction that occurred on Tuesday, July 9th. The stock was sold at an average price of $14.42, for a total value of $71,638.56. The disclosure for this sale can be found here. Insiders sold a total of 1,506,720 shares of company stock valued at $23,046,711 in the last three months. 5.50% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently made changes to their positions in GWPH. Federated Investors Inc. PA lifted its stake in shares of GW Pharmaceuticals PLC- by 23.5% in the 1st quarter. Federated Investors Inc. PA now owns 417,750 shares of the biopharmaceutical company’s stock valued at $70,420,000 after acquiring an additional 79,367 shares during the last quarter. Victory Capital Management Inc. raised its position in GW Pharmaceuticals PLC- by 80.4% during the 1st quarter. Victory Capital Management Inc. now owns 408,940 shares of the biopharmaceutical company’s stock worth $68,935,000 after purchasing an additional 182,210 shares during the last quarter. Marshall Wace North America L.P. grew its holdings in GW Pharmaceuticals PLC- by 1,564.3% during the 1st quarter. Marshall Wace North America L.P. now owns 316,899 shares of the biopharmaceutical company’s stock worth $53,419,000 after acquiring an additional 297,858 shares during the period. Deutsche Bank AG grew its holdings in GW Pharmaceuticals PLC- by 18.2% during the 4th quarter. Deutsche Bank AG now owns 270,575 shares of the biopharmaceutical company’s stock worth $26,350,000 after acquiring an additional 41,593 shares during the period. Finally, Millennium Management LLC acquired a new stake in GW Pharmaceuticals PLC- during the 4th quarter worth about $15,685,000. 78.91% of the stock is currently owned by institutional investors.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Featured Article: NASDAQ Stock Market Explained

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.